In Geneva, Switzerland, on 15 June, the International Generic and Biosimilar Medicines Association (IGBA) welcomed the decision of the ICH General Assembly to accept the IGBA as an assembly member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
‘To join the ICH as an assembly member is a historical moment for our industry. We strongly believe that, having contributed to the ICH work as an interested party over the last 20 years, we can now open a new chapter of engaging fully in the ICH activities of developing the international standards applied to the pharmaceutical industry, including generic and biosimilar manufacturers. The IGBA is very much looking forward to playing a constructive role in the ICH, engaging actively in the ICH processes through the representation of our members across the five continents,’ comments Vivian Frittelli, CEO of the National Association of Pharmaceutical Manufacturers and the chair of the IGBA.
Moving with the times
The positive decision of the ICH to accept IGBA as an assembly member reflects the evolution of the generic and biosimilar pharmaceutical industries. Both are now global industries, with generic medicines accounting for the overwhelming majority of the prescriptions filled worldwide. The development and approval of biosimilars and other complex-to-manufacture medicines also continues to expand.
IGBA is well positioned to continue contributing to the development of the ICH, in collaboration with all members. The IGBA looks forward to participating in the ICH assembly and, in accordance with the new structure, to playing a constructive role in the management committee in the future.